Q1 Earnings Estimate for Acelyrin Issued By HC Wainwright

Acelyrin, Inc. (NASDAQ:SLRN) – Equities researchers at HC Wainwright issued their Q1 2025 EPS estimates for Acelyrin in a report released on Tuesday, January 7th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings of ($0.44) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $6.00 target price on the stock. The consensus estimate for Acelyrin’s current full-year earnings is ($2.57) per share. HC Wainwright also issued estimates for Acelyrin’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at ($2.15) EPS, FY2028 earnings at ($1.58) EPS and FY2029 earnings at ($1.04) EPS.

SLRN has been the subject of a number of other research reports. Wells Fargo & Company lowered their price target on Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Citigroup lowered their target price on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $9.60.

Acelyrin Price Performance

Acelyrin stock opened at $2.14 on Thursday. The stock has a market cap of $214.70 million, a price-to-earnings ratio of -0.87 and a beta of 1.94. The firm has a 50-day moving average of $4.16 and a two-hundred day moving average of $4.84. Acelyrin has a 1 year low of $1.91 and a 1 year high of $8.89.

Institutional Trading of Acelyrin

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. boosted its holdings in shares of Acelyrin by 36.9% in the 3rd quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock valued at $634,000 after buying an additional 34,642 shares in the last quarter. Virtu Financial LLC purchased a new stake in Acelyrin during the third quarter valued at approximately $50,000. Barclays PLC boosted its stake in Acelyrin by 208.8% in the third quarter. Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after acquiring an additional 65,188 shares in the last quarter. Geode Capital Management LLC grew its holdings in Acelyrin by 30.8% in the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock worth $8,144,000 after purchasing an additional 388,631 shares during the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in shares of Acelyrin by 54.6% during the third quarter. Public Employees Retirement System of Ohio now owns 102,347 shares of the company’s stock worth $505,000 after purchasing an additional 36,154 shares in the last quarter. Institutional investors own 87.31% of the company’s stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.